Clinical Trial Update: Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating high-dose methylprednisone followed by ofatumumab and alemtuzumab in 17p deletion CLL/SLL has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Ofatumumab (ofatumumab)
• methylprednisone (methylprednisone)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: CLL, SLL | Phase 2 | Status: TERMINATED | Results posted: 2019-06-26